The ABC(DE) of ADTs in Advanced Prostate Cancer

Prostate cancer is the most common cancer in men in the U.S., responsible for an estimated 248,530 new cases and 34,130 deaths in 2021. For patients diagnosed with advanced prostate cancer, androgen deprivation therapy (ADT) plays a major role in treatment but may be associated with a broad range of adverse effects. Of these, increased risk of cardiovascular (CV) events is among the most serious, as cardiovascular disease (CVD) is the most common non-cancer cause of death in patients with prostate cancer.

For physicians providing care to patients with advanced prostate cancer, staying current on the factors associated with safe, effective ADT use—indications for use, CVD risks, and comparative clinical efficacy of ADT agents—is essential. Of particular importance is the incorporation of the ABCDE algorithm (awareness, blood pressure monitoring, cholesterol management and cigarette avoidance, diet and diabetes, and exercise) into the advanced prostate cancer management paradigm to help prevent and manage CVD in patients with advanced prostate cancer who are receiving ADT.

Developed for urologists, oncologists, and radiation oncologists, this Virtual Practice uses a hands-on, case-based approach to discussing recommended considerations and strategies for managing CVD risk and optimizing outcomes when providing ADT to patients with advanced prostate cancer.